Effect of inclisiran, the siRNA against PCSK9, on platelets, immune cells and immunological biomarkers - a pre-specified analysis from ORION-1

Autor: Landmesser, U, Haghikia, A, Leiter, LA, Wright, RS, Kallend, D, Wijngaard, P, Stoekenbroek, R, Kastelein, JJP, Ray, KK

INTRODUCTION: siRNA-based targeting of PCSK9 represents a novel therapeutic approach that may provide a convenient, infrequent and safe dosing schedule to robustly lower LDL-C. Given the long duration of action, however, establishing safety in partic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::a1871284f9cf60ccf2ac215121c1b7bd
http://hdl.handle.net/10044/1/78216

Pooled Safety and Efficacy of Inclisiran in Patients With Statin Intolerance (ORION-10 and ORION-11)

Autor: McQuillan, B., Wright, R., Kallend, D., Raal, F., Stoekenbroek, R., Koenig, W., Leiter, L., Landmesser, U., Schwartz, G., Wijngaard, P., Kastelein, J., Ray, K.

Publikováno v: In Heart, Lung and Circulation July 2023 32 Supplement 3:S299-S299

Baseline Triglycerides and Non-HDL-C and apoB Goal Attainment in the ORION-10 and ORION-11 Trials

Autor: Ooi, E., Ray, K., Kallend, D., Raal, F., Stoekenbroek, R., Koenig, W., Leiter, L., Landmesser, U., Schwartz, G., Wijngaard, P., Kastelein, J., Wright, R.

Publikováno v: In Heart, Lung and Circulation July 2023 32 Supplement 3:S270-S271

Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.

Autor: Soffer D; Perelman School of Medicine, University of Pennsylvania, 34th and Civic Center Blvd., Philadelphia, PA 19104, USA., Stoekenbroek R; US Clinical Development and Medical Affairs, Novartis Pharmaceuticals Corporation, One Health Plaza, Building 125, East Hanover, NJ 07936, USA. Electronic address: rstoeken@gmail.com., Plakogiannis R; Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 75 Dekalb Avenue, Brooklyn, NY 11201, USA.

Publikováno v: Journal of clinical lipidology [J Clin Lipidol] 2022 Sep-Oct; Vol. 16 (5), pp. 574-582. Date of Electronic Publication: 2022 Jun 28.

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1.

Autor: Landmesser U; Department of Cardiology, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, 10785 Berlin, Germany.; Berlin Institute of Health (BIH), 10178 Berlin, Germany., Haghikia A; Department of Cardiology, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, 10785 Berlin, Germany.; Berlin Institute of Health (BIH), 10178 Berlin, Germany., Leiter LA; The Li Ka Shing Knowledge Institute, Departments of Medicine and Nutritional Sciences, St. Michael's Hospital, University of Toronto, M5B 1W8 Toronto, Canada., Wright RS; Department of Cardiology, Mayo Clinic, Rochester, MN 55905, USA., Kallend D; The Medicines Company, 8001 Zurich, Switzerland., Wijngaard P; The Medicines Company, Parsippany, NJ 07054, USA., Stoekenbroek R; The Medicines Company, Parsippany, NJ 07054, USA., Kastelein JJ; Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands., Ray KK; Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, SW7 2AZ London, UK.

Publikováno v: Cardiovascular research [Cardiovasc Res] 2021 Jan 01; Vol. 117 (1), pp. 284-291.